Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
Fiche publication
Date publication
août 2023
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EBERST Lauriane
Tous les auteurs :
Rodrigues M, Eberst L, Follana P, Gauthier L, Jacquemin V, Tessier C, El Mouaddin N, Boudier P, Fiteni F, Angeli E, Roche S, Delanoy N, Sabatier R, Flippot R, de la Motte Rouge T
Lien Pubmed
Résumé
In October 2020, the French Health Authority granted early access outside of the clinical trial setting for dostarlimab, a programmed death-1 inhibitor. Dostarlimab was approved by the European Medicines Agency (in April 2021) as monotherapy for patients with post-platinum mismatch repair deficient/microsatellite instability-high advanced/recurrent endometrial cancer, based on the results of the GARNET trial (NCT02715284).
Mots clés
ATU, Accès précoce aux médicaments, Dostarlimab, Early access program, Immunotherapy, Immunothérapie, dMMR/MSI-H
Référence
Bull Cancer. 2023 08 31;: